Maxim (NASDAQ:MXIM) Group analyst Jason McCarthy maintained a Buy rating on BeiGene (NASDAQ:BGNE), Ltd. on Friday, setting a price target of $190, which is approximately 17.02% above the present share price of $162.36.
McCarthy expects BeiGene, Ltd. to post earnings per share (EPS) of -$4.68 for the second quarter of 2020.
The current consensus among 7 TipRanks analysts is for a Strong Buy rating of shares in BeiGene, with an average price target of $191.2.
The analysts price targets range from a high of $207 to a low of $169.
In its latest earnings report, released on 03/31/2020, the company reported a quarterly revenue of $52.06 million and a net profit of -$373.76 million. The company's market cap is $12.84 billion.
According to TipRanks.com, Maxim Group analyst Jason McCarthy is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 10.6% and a 42.50% success rate.
BeiGene Ltd. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. It focuses on Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317), and Pamiparib (BGB-290). The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Beijing, China.